Welcome to LookChem.com Sign In|Join Free
  • or
C5E2, also known as Diethylene Glycol Monopentyl Ether, is a compound that has been considered for various applications due to its unique properties. It is particularly noted for its potential use in the pharmaceutical industry, specifically for the delivery of peptide-based pharmaceuticals to the respiratory tract.

18912-81-7

Post Buying Request

18912-81-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18912-81-7 Usage

Uses

Used in Pharmaceutical Industry:
C5E2 is used as a propellant-solution surfactant for the delivery of peptide-based pharmaceuticals to the respiratory tract. Its properties make it a promising candidate for enhancing the effectiveness of such medications, particularly in cases where direct and targeted delivery is required.

Check Digit Verification of cas no

The CAS Registry Mumber 18912-81-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,9,1 and 2 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 18912-81:
(7*1)+(6*8)+(5*9)+(4*1)+(3*2)+(2*8)+(1*1)=127
127 % 10 = 7
So 18912-81-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H20O3/c1-2-3-4-6-11-8-9-12-7-5-10/h10H,2-9H2,1H3

18912-81-7Downstream Products

18912-81-7Relevant academic research and scientific papers

PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

-

Paragraph 00317, (2020/02/16)

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

-

Paragraph 00336, (2018/11/22)

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Combinatorial synthesis of PEG oligomer libraries

-

Page/Page column 9, (2010/02/15)

A simple chain-extending approach was established for the scale-up of the monoprotected monodisperse PEG diol materials. Reactions of THP-(OCH2CH2)n—OMs (n=4, 8, 12) with a large excess of commercially available H—(OCH2CH2)n—OH (n=1-4) under basic conditions led to THP-(OCH2CH2)n—OH (n=5-15). Similarly, Me-(OCH2CH2)n—OH (n=4-11, 13) were prepared from Me-(OCH2CH2)n—OMs (n=3, 7, 11). For the chain elongation steps, 40-80% yields were achieved through extraction purification. PEG oligomer libraries I and II were generated in 50-95% overall yields by alkylation or acylation of THP-(OCH2CH2)n—OH (n=1-15) followed by deprotection. Alkylation of Me-(OCH2CH2)n—OH (n=1-11, 13) with X—(CH2)m—CO2R (X=Br or OMs) and subsequent hydrolysis led to PEG oligomer library III in 30-60% overall yields. Combinatorial purification techniques were adapted to the larger-scale library synthesis. A total of 498 compounds, each with a weight of 2-5 g and a minimum purity of 90%, were synthesized.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 18912-81-7